



CLINICAL AND REAL-WORLD STUDIES SHOW



SPINRAZA™ HELPS PATIENTS DO MORE, COMPARED WITH SHAM-CONTROL AND NATURAL HISTORY<sup>1,2</sup>

Individual results may vary from patient to patient and based on progression of the disease and duration of therapy. In pivotal randomised controlled trials, SPINRAZA™ demonstrated clinically and statistically meaningful improvements in motor function compared with sham-control.<sup>1</sup> In supportive and real-world studies, pre-symptomatic patients through adults improved relative to natural history.<sup>1,2</sup>

## Invitation

Dear Doctor,

we cordially invite you to

explore **MORE** possibilities with SPINRAZA™, the **first and only** ASO (antisense oligonucleotide) treatment indicated for SMA (Spinal Muscular Atrophy) in pediatric and adult patients, with **13,000+** patients treated worldwide\*

# SPINRAZA™ Oman Launch Event



W Hotel, Muscat, Oman



Friday 29<sup>th</sup> Sep. 2023



4:00 PM - 8:30 PM  
(Oman Time)

# Faculty

in alphabetical order



**Dr Abdullah Al Salti**

MD, MFCP(UK), FRCPC, CSCN

Sr Consultant neurologist,  
neuromuscular & EMG specialist,  
Khoula Hospital, Muscat, Oman



**Prof. Ali Al Shehri**

MD

Assistant Professor, King Faisal  
Specialist Hospital and Research  
Centre | KFSHRC, KSA



**Prof. Amna Al Futaisi**

MD, FRCPC, FRCPCH

Ass. Professor & Senior Consultant  
Pediatric Neurology, Sultan Qaboos  
University, Muscat, Oman



**Prof. Anna  
Kostera-Pruszczyk**

Head of the Department and Clinic of  
Neurology at UCK WUM, Poland



**Prof. Eduardo Tizzano**

MD, PhD

Director of department of Clinical  
and Molecular Genetics, Vall  
d'Hebron Hospital, Barcelona,  
Spain



**Dr Farzad Fatehi**

MD, MSc

Consultant Neurologist, Khoula  
Hospital, Muscat, Oman



**Jokha Al Barwani**

Senior Pediatric Physical Therapist,  
Medical Rehabilitation  
Department, Royal Hospital, Oman



**Dr Nabil Al Macki**

MD/MRCPCH/FRCPC

Sr Consultant Pediatric Neurologist,  
Head of pediatric Neurology  
Department Royal Hospital, Muscat,  
Oman



**Safiya Al Bahlani**

Artist, Creative Designer,  
Inspirational & Motivational  
Speaker  
CEO- Safiya Arts Gallery, Oman



**Said Wani Said  
Al-Bakdi**

# Agenda

Time (Oman)	Topic	Speaker
4:00 - 4:10 PM	Ringin Welcome Message	Diedrik Kok - Ringin GM
<b>Session 1 - Know SMA</b> Chairperson: Dr Nabil Al Macki		
4:10 - 4:25 PM	MORE is Possible	Safiya Al Bahlani 
4:25 - 4:45 PM	Know SMA: Clinical Presentation and Genetics	Prof. Anna Al Futaisi 
4:45 - 5:05 PM	Burden of SMA Disease in Oman	Said Wani Said Al-Rashdi 
5:05 - 5:25 PM	Standards of Care in SMA and the Role of the Multi-Disciplinary Team	Prof. Eduardo Tizzano 
5:25 - 5:40 PM	Physiotherapy Care in SMA	Jokha Al Barwani 
5:40 - 5:55 PM	Q & A: Panel Discussion	All
<b>5:55 - 6:15 PM</b> Coffee Break		
<b>Session 2 - MORE is Possible with SPINRAZA™</b> Chairperson: Dr Abdullah Al- Salti		
6:15 - 6:35 PM	The Evolving Landscape in SMA: Overview of The Emergent Phenotypes	Prof. Eduardo Tizzano 
6:35 - 6:55 PM	MORE is Possible with SPINRAZA™ in Children Living with SMA	Prof. Eduardo Tizzano 
6:55 - 7:10 PM	SPINRAZA™ Clinical Experience in Omani Children with SMA	Dr Nabil Al Macki 
7:10 - 7:25 PM	Adult SMA in Focus	Prof. Anna Kostera-Pruszczyk 
7:25 - 7:40 PM	Adult SMA in Oman: The Road to Diagnosis	Dr Farzad Fatehi 
7:40 - 8:00 PM	MORE is Possible with SPINRAZA™ in Adults Living with SMA	Prof. Anna Kostera-Pruszczyk 
8:00 - 8:15 PM	SPINRAZA™ Clinical Experience in Saudi Adults Living with SMA	Prof. Ali Al Shehri 
8:15 - 8:30 PM	Q & A: Panel Discussion	All
<b>8:30 PM</b> Dinner		

SMA=Spinal muscular atrophy.

Pictures depicted are inspired by real people living with SMA and are for illustrative purposes only.

1. SPINRAZA™ Summary of Product Characteristics. 2. Coratti G, et al. Orphanet J Rare Dis. 2021;16:430.

\*Based on commercial patients, early access patients, and clinical trial participants through May 2022.

Endorsed by

الرابطة العُمانية  
لطب المخ  
والاعصاب



Oman  
Neurology  
Society